325P Trends of primary tumor resection in de novo metastatic breast cancer: The experience of a Mexican center

Abstract

were receiving first line ET at a single institution. Two cohorts were defined: ET alone (2012-2104, prior to approval of CDK 4/6i) and ET+ CDK 4/6i (2015-2017. Data was extracted from the electronic medical record (EPIC) and entered into a REDCap database: demographics, CVD, comorbidities, cardiac medication/procedures, and HCU. Summary statistics include medians and interquartile ranges for continuous variables and frequencies and percentages for categorial variables. Results:The study population included 108 patients: 62 on ET alone and 46 on ET+CDK4/ 6i. Median age was 61.5 and 63.5 years, respectively. Baseline characteristics were similar between groups (data not shown). CVD and HCU are presented in the table. Conclusions:In this retrospective single institution cohort study, baseline CVD and HCU during treatment was similar in pts prescribed ET alone and ET + CDK4/6i. Presence of CVD did not seem to dissuade practitioners from prescribing ET + CDK4/ 6i. Further research is needed to understand the impact of CDK4/6i on CV health and HCU in a larger cohort of pts.